カテゴリー： MarketsandMarkets, 世界, 医療/バイオ

世界のマイクロバイオーム診断市場（～2028年）：製品別（キット＆試薬、機器）、技術別（16srRNAシーケンシング、ショットガンメタゲノミクス、メタトランスクリプトミクス）、サンプル別（便、唾液、皮膚）、用途別（消化管、代謝異常）

◆英語タイトル：Microbiome Diagnostics Market by Product (Kits & Reagents, Instruments), Technology (16s rRNA Sequencing, Shot Gun Metagenomics, Metatranscriptomics), Sample (Fecal, Saliva, Skin), Application (GI, Metabolic Disorders) - Global Forecast to 2028
	◆商品コード：MD8949-24 ◆発行会社（リサーチ会社）：MarketsandMarkets ◆発行日：2024年2月 ◆ページ数：179 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後24時間以内） ◆調査対象地域：グローバル ◆産業分野：医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧）	USD4,950 ⇒換算￥752,400	見積依頼/購入/質問フォーム
Multi User (Five User)	USD6,650 ⇒換算￥1,010,800	見積依頼/購入/質問フォーム
Corporate License (全社内共有可)	USD8,150 ⇒換算￥1,238,800	見積依頼/購入/質問フォーム

★MarketsandMarketsに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

“マイクロバイオーム診断の世界市場は2023年に推定1億4600万米ドルと評価され、予測期間中に15.5％のCAGRで成長し、2028年までに3億米ドルに達すると予測”市場成長の原動力は、マイクロバイオーム診断の認知度向上、個別化医療の需要増加、疾患の発生率増加などの要因です。

“マイクロバイオーム診断市場の製品別シェアは試薬・キットが最大に”
世界のマイクロバイオーム診断市場は、製品別に試薬＆キットと機器に区分されます。市場成長の主な原動力となるのは、微生物学に基づく診断手順における試薬・キットの反復使用と、世界中で実施される微生物学に基づく検査量の増加です。さらに、効率的な結果と診断の精度を提供する優れた試薬・キットが入手可能になったことが、このセグメントの成長をもたらしています。

“予測期間中、16s rRNAシーケンシング分野は技術の中でかなりの成長率で成長する見込み”
マイクロバイオーム診断市場は、16s rRNAシーケンス、ショットガン・メタゲノミクス、メタトランスクリプトミクス、その他の技術に区分されます。キャピラリーシーケンスやPCRベースのアプローチと比較して、16S rRNAシーケンスは培養を必要としない技術であり、研究者はサンプル内の微生物群集全体を分析することができます。1回のシーケンス実行で多数のサンプルを組み合わせることができるため、NGSベースの16S rRNAシーケンスは、従来の方法では見つからない可能性のある細菌株を同定するためのコスト効率の高い手法です。

“用途別シェアは研究用途セグメントが最大に”
世界のマイクロバイオーム診断市場は、研究用途、疾患診断用途にセグメント化されます。2022年には、主に疾患の有病率の上昇により、疾患診断用途セグメントがかなりのシェアを占めました。

“アジア太平洋地域：マイクロバイオーム診断薬市場で最も急成長している地域”
世界のマイクロバイオーム診断市場は、北米、欧州、アジア太平洋地域、その他の地域の5地域に区分されます。アジア太平洋地域は、マイクロバイオーム診断市場において予測期間中に最も高い成長が見込まれています。同地域の高成長の背景には、アジア諸国における疾患の増加、マイクロバイオーム研究活動の活発化があります。

マイクロバイオーム診断市場における主要参入企業のプロファイルの内訳：
- 企業タイプ別：ティア1：55%、ティア2：40%、ティア3：5%
- 役職別 Cレベル：37%、Dレベル：48%、その他：15%
- 地域別北米：56%、ヨーロッパ：20%、アジア太平洋地域：17%、その他の地域：7%

この市場の主要企業は、DNA Genotek（カナダ）、Invivo Healthcare（英国）、Microba Life Sciences（米国）、Genetic Analysis AS（ノルウェー）、Metabiomics（米国）、Teraomics（米国）、Becton, Dickinson and Company（米国）、BioMe Oxford Ltd（英国）、Viennalab Diagnostics（オーストリア）、Viome Life Sciences, Inc. （米国）、Luxia Scientific（フランス）、DayTwo（米国）、Sun Genomics（米国）、Atlas Biomed（英国）、Quantbiome（米国）、GoodGut（米国）、Micronoma（米国）、FlightPath Biosciences（米国）、Microbiome Research Pvt. Ltd.（インド）などです。

調査範囲
本調査レポートは、マイクロバイオーム診断市場を製品別（試薬＆キット、機器）、サンプル別（便、唾液、皮膚、その他サンプル）、技術別（16s rRNAシーケンス、ショットガンメタゲノミクス、メタトランスクリプトミクス、その他技術）、用途別（研究用途、疾患診断、モニタリング）、エンドユーザー別（研究機関、製薬・バイオ企業、病院、その他エンドユーザー）、地域別（北米、欧州、アジア太平洋地域、その他地域）に分類しています。マイクロバイオーム診断市場の成長に影響を与える促進要因、機会、課題などの主要要因に関する詳細情報を網羅しています。主要な産業プレイヤーを詳細に分析し、事業概要、提供製品、主要戦略、買収、提携に関する洞察を提供します。マイクロバイオーム診断薬市場に関連する新製品の上市や承認、最近の動向。マイクロバイオーム診断市場のエコシステムにおける今後の新興企業の競合分析もカバーしています。

本レポートを購入する理由
本レポートは、マイクロバイオーム診断薬市場全体およびサブセグメントの収益数の最も近い近似値に関する情報を提供することで、本市場の市場リーダー/新規参入者に役立ちます。本レポートは、ステークホルダーが競合状況を理解し、より深い洞察を得ることで、事業の位置づけを高め、適切な市場参入戦略を計画するのに役立ちます。また、本レポートは、関係者が市場の鼓動を理解するのに役立ち、主要な市場促進要因、阻害要因、課題、機会に関する情報を提供します。

本レポートでは、以下のポイントに関する洞察を提供しています：
- 主要な促進要因（マイクロバイオーム研究のためのマイクロバイオーム産業と学界の協力体制、個別化医療に対する需要の高まり、ヒトマイクロバイオーム診断の重要性に対する認識の高まり、疾病の発生率の上昇）、機会（新たなマイクロバイオーム技術に取り組む主要企業と小規模な革新的企業との協力関係の増加）、および課題（マイクロバイオームベースの市場の成長に影響を与える複雑な規制政策による商業化への悪影響）の分析
- 製品開発／イノベーション：マイクロバイオーム診断市場における今後の技術、研究開発活動、新製品発売に関する詳細な洞察。
- 市場開発：有利な市場に関する包括的な情報 - 本レポートでは、さまざまな地域のマイクロバイオーム診断市場を分析しています。
- 市場の多様化：マイクロバイオーム診断薬市場における新製品、未開拓地域、最近の開発、投資に関する詳細な情報
- 競合評価： DNA Genotek社（カナダ）、Invivo Healthcare社（英国）、Microba Life Sciences社（米国）、Genetic Analysis AS社（ノルウェー）など、マイクロバイオーム診断市場戦略における主要企業の市場シェア、成長戦略、製品提供などを詳細に評価。

1 はじめに
2 調査方法
3 エグゼクティブサマリー
4 プレミアムインサイト
5 市場概要
6 マイクロバイオーム診断市場：製品別
7 マイクロバイオーム診断市場：技術別
8 マイクロバイオーム診断市場：サンプル別
9 マイクロバイオーム診断市場：用途別
10 マイクロバイオーム診断市場：エンドユーザー別
11 マイクロバイオーム診断市場：地域別
12 競争状況
13 企業プロファイル
14 付録

❖ レポートの目次 ❖

1 INTRODUCTION 26
1.1 STUDY OBJECTIVES 26
1.2 MARKET DEFINITION 26
TABLE 1 INCLUSIONS & EXCLUSIONS 27
1.3 STUDY SCOPE 27
FIGURE 1 MICROBIOME-BASED DIAGNOSTICS MARKET SCOPE 27
1.3.1 YEARS CONSIDERED 28
1.4 CURRENCY CONSIDERED 28
1.5 STAKEHOLDERS 28
2 RESEARCH METHODOLOGY 29
2.1 RESEARCH DATA 29
FIGURE 2 MICROBIOME-BASED DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY 29
2.1.1 SECONDARY DATA 30
2.1.1.1 Key data from secondary sources 31
2.1.2 PRIMARY DATA 32
FIGURE 3 PRIMARY SOURCES 32
2.1.2.1 Key data from primary sources 33
2.1.2.2 Key industry insights 34
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 34
2.1.2.3 Breakdown of primary interviews 35
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 35
2.2 MARKET SIZE ESTIMATION 35
2.2.1 BOTTOM-UP APPROACH 35
2.2.1.1 Approach 1: Company revenue estimation approach 36
FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 36
2.2.1.2 Approach 2: Presentations of companies and primary interviews 36
2.2.1.3 Approach 3: Primary research 36
2.2.1.4 Growth forecast 37
2.2.1.5 CAGR projections 37
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 37
2.2.2 TOP-DOWN APPROACH 37
FIGURE 8 MICROBIOME-BASED DIAGNOSTICS MARKET: TOP-DOWN APPROACH 38
2.3 DATA TRIANGULATION 39
FIGURE 9 DATA TRIANGULATION METHODOLOGY 39
2.4 STUDY ASSUMPTIONS 40
2.5 RESEARCH LIMITATIONS AND RISK ASSESSMENT 40
TABLE 2 RISK ASSESSMENT: MICROBIOME-BASED DIAGNOSTICS MARKET 41
2.6 IMPACT OF RECESSION ON MICROBIOME-BASED DIAGNOSTICS MARKET 41
3 EXECUTIVE SUMMARY 43
FIGURE 10 MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 43
FIGURE 11 MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 44
FIGURE 12 MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2023 VS. 2028 (USD MILLION) 44
FIGURE 13 MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 45
FIGURE 14 MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 46
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF MICROBIOME-BASED DIAGNOSTICS MARKET 47
4 PREMIUM INSIGHTS 48
4.1 MICROBIOME-BASED DIAGNOSTICS MARKET OVERVIEW 48
FIGURE 16 RISING DISEASE INCIDENCE AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET GROWTH 48
4.2 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT & COUNTRY (2022) 49
FIGURE 17 KITS & REAGENTS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022 49
4.3 MICROBIOME-BASED DIAGNOSTICS MARKET: GEOGRAPHICAL SNAPSHOT 50
FIGURE 18 CHINA AND INDIA TO WITNESS HIGHEST GROWTH RATES DURING FORECAST PERIOD 50
4.4 MICROBIOME-BASED DIAGNOSTICS MARKET: GEOGRAPHIC MIX 51
FIGURE 19 APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 51
4.5 MICROBIOME-BASED DIAGNOSTICS MARKET: DEVELOPED VS. EMERGING ECONOMIES 51
FIGURE 20 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 51
5 MARKET OVERVIEW 52
5.1 INTRODUCTION 52
5.2 MARKET DYNAMICS 52
FIGURE 21 MICROBIOME-BASED DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 52
5.2.1 DRIVERS 53
5.2.1.1 Growing prevalence of chronic diseases 53
FIGURE 22 GLOBAL INCIDENCE OF DIABETES, 2021 VS. 2045 53
5.2.1.2 Collaborative efforts between microbiome industry and academia for microbiome research 53
5.2.1.3 Growing demand for personalized medicine 54
5.2.1.4 Rising awareness about importance of human microbiomes 54
5.2.1.5 Rising funding and investments in microbiome research 55
5.2.2 RESTRAINTS 55
5.2.2.1 End-user budget constraints in developing countries 55
5.2.3 OPPORTUNITIES 56
5.2.3.1 Increased collaboration between key players and small innovative companies to work on new microbiome technologies 56
TABLE 3 COLLABORATIONS IN MICROBIOME-BASED DIAGNOSTICS MARKET 56
5.2.4 CHALLENGES 56
5.2.4.1 Adverse impact of complex regulatory policies on commercialization of microbiome 56
5.3 VALUE CHAIN ANALYSIS 57
FIGURE 23 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 57
5.4 SUPPLY CHAIN ANALYSIS 58
FIGURE 24 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES 58
5.5 PORTER’S FIVE FORCES ANALYSIS 59
5.5.1 THREAT OF NEW ENTRANTS 59
5.5.2 INTENSITY OF COMPETITIVE RIVALRY 59
5.5.3 BARGAINING POWER OF BUYERS 59
5.5.4 BARGAINING POWER OF SUPPLIERS 59
5.5.5 THREAT OF SUBSTITUTES 59
5.6 KEY STAKEHOLDERS & BUYING CRITERIA 60
5.6.1 KEY STAKEHOLDERS IN BUYING PROCESS 60
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 2 END USERS 60
5.6.2 BUYING CRITERIA 60
FIGURE 26 KEY BUYING CRITERIA FOR TOP 2 END USERS 60
5.7 REGULATORY LANDSCAPE 61
5.7.1 NORTH AMERICA 61
TABLE 4 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 61
5.7.2 EUROPE 61
TABLE 5 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 61
5.7.3 ASIA PACIFIC 62
TABLE 6 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 62
5.7.4 REST OF THE WORLD 63
TABLE 7 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63
5.8 ECOSYSTEM ANALYSIS 63
TABLE 8 ROLE IN ECOSYSTEM 63
FIGURE 27 KEY PLAYERS OPERATING IN MICROBIOME-BASED DIAGNOSTICS MARKET 64
5.9 PATENT ANALYSIS 65
5.10 KEY CONFERENCES & EVENTS 66
TABLE 9 LIST OF CONFERENCES & EVENTS IN 2023–2024 66
5.11 PRICING ANALYSIS 66
5.11.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY APPLICATION 66
TABLE 10 PRICE RANGE OF PRODUCTS OFFERED BY KEY PLAYERS FOR APPLICATIONS (USD) 66
5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 67
5.13 TECHNOLOGY ANALYSIS 67
5.13.1 DEVELOPMENT OF NOVEL MICROBIOME SAMPLING DEVICES 67
5.14 TRADE ANALYSIS 68
TABLE 11 IMPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2021 (USD MILLION) 68
TABLE 12 EXPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2021 (USD MILLION) 68
6 MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT 69
6.1 INTRODUCTION 70
TABLE 13 MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 70
6.2 KITS & REAGENTS 70
6.2.1 KITS & REAGENTS TO DOMINATE MICROBIOME-BASED DIAGNOSTICS MARKET DURING FORECAST PERIOD 70
TABLE 14 MICROBIOME-BASED DIAGNOSTIC KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 71
6.3 INSTRUMENTS 71
6.3.1 INCREASING VOLUME OF BLOOD COLLECTION PROCEDURES TO DRIVE MARKET GROWTH 71
TABLE 15 MICROBIOME-BASED DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 72
7 MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY 73
7.1 INTRODUCTION 74
TABLE 16 MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 74
7.2 16S RRNA SEQUENCING 74
7.2.1 ABILITY TO COMBINE MANY SAMPLES IN SEQUENCING RUN TO DRIVE DEMAND FOR NGS-BASED 16S RRNA SEQUENCING 74
TABLE 17 MICROBIOME-BASED DIAGNOSTICS MARKET FOR 16S RRNA SEQUENCING, BY REGION, 2021–2028 (USD MILLION) 75
7.3 SHOTGUN METAGENOMICS 75
7.3.1 ABILITY OF SHOTGUN METAGENOMICS TO PROVIDE DETAILED GENETIC INFORMATION TO BOOST DEMAND 75
TABLE 18 COMPARISON BETWEEN SHOTGUN METAGENOMICS AND 16S RRNA SEQUENCING 75
TABLE 19 MICROBIOME-BASED DIAGNOSTICS MARKET FOR SHOTGUN METAGENOMICS, BY REGION, 2021–2028 (USD MILLION) 76
7.4 METATRANSCRIPTOMICS 76
7.4.1 ONGOING TECHNOLOGICAL ADVANCEMENTS IN SEQUENCING INSTRUMENTS TO DRIVE GROWTH 76
TABLE 20 MICROBIOME-BASED DIAGNOSTICS MARKET FOR METATRANSCRIPTOMICS, BY REGION, 2021–2028 (USD MILLION) 77
7.5 OTHER TECHNOLOGIES 77
TABLE 21 MICROBIOME-BASED DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION) 77
8 MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE 78
8.1 INTRODUCTION 79
TABLE 22 MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION) 79
8.2 FECAL SAMPLES 79
8.2.1 FECAL SAMPLES TO DOMINATE MICROBIOME-BASED DIAGNOSTICS MARKET DURING FORECAST PERIOD 79
TABLE 23 LIST OF MICROBIOME-BASED DIAGNOSTIC KITS FOR FECAL SAMPLES 79
TABLE 24 MICROBIOME-BASED DIAGNOSTICS MARKET FOR FECAL SAMPLES, BY REGION, 2021–2028 (USD MILLION) 80
8.3 SALIVA SAMPLES 80
8.3.1 ADVANCEMENTS IN ORAL DIAGNOSTICS TO DRIVE MARKET GROWTH 80
TABLE 25 LIST OF MICROBIOME-BASED DIAGNOSTIC KITS FOR SALIVA SAMPLES 80
TABLE 26 MICROBIOME-BASED DIAGNOSTICS MARKET FOR SALIVA SAMPLES, BY REGION, 2021–2028 (USD MILLION) 81
8.4 SKIN SAMPLES 81
8.4.1 GROWING FOCUS ON MICROBIOME RESEARCH ACTIVITIES TO BOOST MARKET 81
TABLE 27 LIST OF MICROBIOME-BASED DIAGNOSTIC KITS FOR SKIN SAMPLES 81
TABLE 28 MICROBIOME-BASED DIAGNOSTICS MARKET FOR SKIN SAMPLES, BY REGION, 2021–2028 (USD MILLION) 82
8.5 OTHER SAMPLES 82
TABLE 29 LIST OF MICROBIOME-BASED DIAGNOSTIC KITS FOR OTHER SAMPLES 82
TABLE 30 MICROBIOME-BASED DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY REGION, 2021–2028 (USD MILLION) 82
9 MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION 83
9.1 INTRODUCTION 84
TABLE 31 MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 84
9.2 DISEASE DIAGNOSTIC APPLICATIONS 84
TABLE 32 MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 85
TABLE 33 MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 85
9.2.1 GASTROINTESTINAL DISORDERS 85
9.2.1.1 Growing incidence of gastrointestinal disorders to drive market growth 85
TABLE 34 MICROBIOME-BASED DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 86
9.2.2 METABOLIC DISORDERS 86
9.2.2.1 High prevalence of metabolic disorders to drive demand for microbiome-based diagnostic products 86
TABLE 35 MICROBIOME-BASED DIAGNOSTICS MARKET FOR METABOLIC DISORDERS, BY REGION, 2021–2028 (USD MILLION) 87
9.2.3 OTHER DISEASE DIAGNOSTIC APPLICATIONS 87
TABLE 36 MICROBIOME-BASED DIAGNOSTICS MARKET FOR OTHER DISEASE DIAGNOSTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 87
9.3 RESEARCH APPLICATIONS 88
9.3.1 GROWING RESEARCH ACTIVITIES TO BOOST MARKET 88
TABLE 37 MICROBIOME-BASED DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 88
10 MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER 89
10.1 INTRODUCTION 90
TABLE 38 MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 90
10.2 HOSPITALS 90
10.2.1 HOSPITALS ACCOUNTED FOR LARGEST SHARE OF MICROBIOME-BASED DIAGNOSTICS MARKET IN 2022 90
TABLE 39 MICROBIOME-BASED DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION) 90
10.3 RESEARCH INSTITUTES 91
10.3.1 GROWING FUNDING FOR MICROBIOME RESEARCH TO SUPPORT MARKET GROWTH 91
TABLE 40 MICROBIOME-BASED DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 91
10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 92
10.4.1 GROWING FOCUS ON PERSONALIZED MEDICINE TO DRIVE DEMAND FOR MICROBIOME-BASED PRODUCTS 92
TABLE 41 MICROBIOME-BASED DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 92
11 MICROBIOME-BASED DIAGNOSTICS MARKET, BY REGION 93
11.1 INTRODUCTION 94
TABLE 42 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY REGION, 2021–2028 (USD MILLION) 94
11.2 NORTH AMERICA 94
FIGURE 28 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET SNAPSHOT 95
TABLE 43 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 96
TABLE 44 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 96
TABLE 45 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 96
TABLE 46 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION) 97
TABLE 47 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 97
TABLE 48 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 97
TABLE 49 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 98
11.2.1 US 98
11.2.1.1 US to account for largest share of during forecast period 98
TABLE 50 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 99
TABLE 51 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 99
TABLE 52 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION) 99
TABLE 53 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 100
TABLE 54 US: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 100
TABLE 55 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 100
11.2.2 CANADA 101
11.2.2.1 High prevalence of diseases in Canada to support market growth 101
TABLE 56 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 101
TABLE 57 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 101
TABLE 58 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION) 102
TABLE 59 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 102
TABLE 60 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 102
TABLE 61 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 103
11.2.3 NORTH AMERICA: RECESSION IMPACT 103
11.3 EUROPE 104
TABLE 62 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 63 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 104
TABLE 64 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 105
TABLE 65 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION) 105
TABLE 66 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 105
TABLE 67 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 106
TABLE 68 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 106
11.3.1 GERMANY 106
11.3.1.1 Germany to dominate European microbiome-based diagnostics market during forecast period 106
TABLE 69 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 107
TABLE 70 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 107
TABLE 71 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION) 107
TABLE 72 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 108
TABLE 73 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 108
TABLE 74 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 108
11.3.2 FRANCE 109
11.3.2.1 Growing number of microbiome sequencing start-ups to boost market growth 109
TABLE 75 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 109
TABLE 76 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 109
TABLE 77 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION) 110
TABLE 78 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 110
TABLE 79 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 110
TABLE 80 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 111
11.3.3 UK 111
11.3.3.1 Supportive environment for microbiome sequencing R&D to support growth 111
TABLE 81 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 111
TABLE 82 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 112
TABLE 83 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION) 112
TABLE 84 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 112
TABLE 85 UK: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 113
TABLE 86 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 113
11.3.4 REST OF EUROPE 113
TABLE 87 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 114
TABLE 88 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 114
TABLE 89 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION) 115
TABLE 90 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 115
TABLE 91 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 115
TABLE 92 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 116
11.3.5 EUROPE: RECESSION IMPACT 116
11.4 ASIA PACIFIC 117
FIGURE 29 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET SNAPSHOT 117
TABLE 93 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 94 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 118
TABLE 95 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 118
TABLE 96 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION) 119
TABLE 97 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 119
TABLE 98 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 119
TABLE 99 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 120
11.4.1 CHINA 120
11.4.1.1 Collaborations between academic institutes and private companies to drive growth 120
TABLE 100 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 121
TABLE 101 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 121
TABLE 102 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION) 121
TABLE 103 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 122
TABLE 104 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 122
TABLE 105 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 122
11.4.2 JAPAN 123
11.4.2.1 Rising aging population to drive market growth 123
TABLE 106 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 123
TABLE 107 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 123
TABLE 108 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION) 124
TABLE 109 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 124
TABLE 110 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 124
TABLE 111 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 125
11.4.3 INDIA 125
11.4.3.1 Increasing prevalence of diseases to drive market growth 125
TABLE 112 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 126
TABLE 113 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 126
TABLE 114 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION) 126
TABLE 115 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 127
TABLE 116 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 127
TABLE 117 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 127
11.4.4 REST OF ASIA PACIFIC 128
TABLE 118 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 128
TABLE 119 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 128
TABLE 120 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION) 129
TABLE 121 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 129
TABLE 122 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 129
TABLE 123 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 130
11.4.5 ASIA PACIFIC: RECESSION IMPACT 130
11.5 REST OF THE WORLD 131
TABLE 124 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 131
TABLE 125 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 131
TABLE 126 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION) 132
TABLE 127 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 132
TABLE 128 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 132
TABLE 129 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 133
11.5.1 REST OF THE WORLD: RECESSION IMPACT 133
12 COMPETITIVE LANDSCAPE 134
12.1 OVERVIEW 134
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 134
TABLE 130 OVERVIEW OF STRATEGIES ADOPTED BY KEY MICROBIOME-BASED DIAGNOSTIC MANUFACTURERS 134
12.3 REVENUE ANALYSIS 136
FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS 136
12.4 MARKET SHARE ANALYSIS 137
TABLE 131 MICROBIOME-BASED DIAGNOSTICS MARKET: DEGREE OF COMPETITION 137
12.5 COMPANY EVALUATION MATRIX 138
12.5.1 STARS 138
12.5.2 EMERGING LEADERS 138
12.5.3 PERVASIVE PLAYERS 138
12.5.4 PARTICIPANTS 138
FIGURE 31 MICROBIOME-BASED DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX 139
12.5.5 COMPANY FOOTPRINT ANALYSIS 140
TABLE 132 COMPANY FOOTPRINT 140
TABLE 133 COMPANY PRODUCT FOOTPRINT 141
TABLE 134 COMPANY REGIONAL FOOTPRINT 142
12.6 START-UP/SME EVALUATION MATRIX 143
12.6.1 PROGRESSIVE COMPANIES 143
12.6.2 RESPONSIVE COMPANIES 143
12.6.3 DYNAMIC COMPANIES 143
12.6.4 STARTING BLOCKS 143
FIGURE 32 MICROBIOME-BASED DIAGNOSTICS MARKET: START-UP/SME EVALUATION MATRIX, 2022 144
12.6.5 COMPETITIVE BENCHMARKING 145
TABLE 135 MICROBIOME-BASED DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES 145
12.7 COMPETITIVE SCENARIO & TRENDS 145
12.7.1 PRODUCT LAUNCHES & APPROVALS 145
TABLE 136 MICROBIOME-BASED DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, 2020–2023 145
12.7.2 DEALS 146
TABLE 137 MICROBIOME-BASED DIAGNOSTICS MARKET: DEALS, 2020–2023 146

13 COMPANY PROFILES 147
13.1 KEY PLAYERS 147
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
13.1.1 GENETIC ANALYSIS AS 147
TABLE 138 GENETIC ANALYSIS AS: COMPANY OVERVIEW 147
FIGURE 33 GENETIC ANALYSIS AS: COMPANY SNAPSHOT (2022) 148
13.1.2 DNA GENOTEK (ORASURE TECHNOLOGIES, INC.) 151
TABLE 139 DNA GENOTEK: COMPANY OVERVIEW 151
FIGURE 34 ORASURE TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022) 152
13.1.3 MICROBA LIFE SCIENCES 154
TABLE 140 MICROBA LIFE SCIENCES: COMPANY OVERVIEW 154
FIGURE 35 MICROBA LIFE SCIENCES: COMPANY SNAPSHOT (2023) 155
13.1.4 ILLUMINA INC. 157
TABLE 141 ILLUMINA INC.: COMPANY OVERVIEW 157
FIGURE 36 ILLUMINA INC.: COMPANY SNAPSHOT (2022) 158
13.1.5 OXFORD NANOPORE TECHNOLOGIES, PLC 160
TABLE 142 OXFORD NANOPORE TECHNOLOGIES, PLC: COMPANY OVERVIEW 160
FIGURE 37 OXFORD NANOPORE TECHNOLOGIES, PLC.: COMPANY SNAPSHOT (2022) 161
13.1.6 BIOME OXFORD LTD. 162
TABLE 143 BIOME OXFORD LTD.: COMPANY OVERVIEW 162
13.1.7 VIENNALAB DIAGNOSTICS GMBH 163
TABLE 144 VIENNALAB DIAGNOSTICS GMBH: COMPANY OVERVIEW 163
13.1.8 METABIOMICS (A SUBSIDIARY OF PRESCIENT MEDICINE HOLDINGS, INC.) 164
TABLE 145 METABIOMICS: COMPANY OVERVIEW 164
13.1.9 VIOME LIFE SCIENCES 165
TABLE 146 VIOME LIFE SCIENCES: COMPANY OVERVIEW 165
13.1.10 LUXIA SCIENTIFIC 166
TABLE 147 LUXIA SCIENTIFIC: COMPANY OVERVIEW 166
13.1.11 SUN GENOMICS 167
TABLE 148 SUN GENOMICS: COMPANY OVERVIEW 167
13.1.12 ATLAS BIOMED 168
TABLE 149 ATLAS BIOMED: COMPANY OVERVIEW 168
13.1.13 QUANTBIOME, INC. (DBA OMBRE) 169
TABLE 150 QUANTBIOME, INC.: COMPANY OVERVIEW 169
13.1.14 BECTON, DICKINSON AND COMPANY 170
TABLE 151 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 170
FIGURE 38 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022) 171
13.1.15 DAYTWO 172
TABLE 152 DAYTWO: COMPANY OVERVIEW 172
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.

13.2 OTHER PLAYERS 173
13.2.1 MICRONOMA 173
13.2.2 TERAOMICS S.L. 173
13.2.3 FLIGHTPATH BIOSCIENCES 174
13.2.4 MICROBIOME RESEARCH PVT. LTD. 174
13.2.5 ORIGIN SCIENCES 175
13.2.6 LEUCINE RICH BIO PRIVATE LIMITED 175
13.2.7 DECODE AGE 176
13.2.8 EVVY 176
13.2.9 ALPHABIOMICS, LTD. 176
13.2.10 GOODGUT 177
14 APPENDIX 178
14.1 DISCUSSION GUIDE 178
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 182
14.3 CUSTOMIZATION OPTIONS 184
14.4 RELATED REPORTS 184
14.5 AUTHOR DETAILS 185

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のマイクロバイオーム診断市場（～2028年）：製品別（キット＆試薬、機器）、技術別（16srRNAシーケンシング、ショットガンメタゲノミクス、メタトランスクリプトミクス）、サンプル別（便、唾液、皮膚）、用途別（消化管、代謝異常）(Microbiome Diagnostics Market by Product (Kits & Reagents, Instruments), Technology (16s rRNA Sequencing, Shot Gun Metagenomics, Metatranscriptomics), Sample (Fecal, Saliva, Skin), Application (GI, Metabolic Disorders) - Global Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp